Clinical Trials Logo

Lymphoid Leukemia clinical trials

View clinical trials related to Lymphoid Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04155840 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: January 31, 2020
Phase: Phase 2
Study type: Interventional

This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine and rituximab, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bendamustine and rituximab with copanlisib may work better than bendamustine and rituximab alone in treating chronic lymphocytic leukemia or small lymphocytic lymphoma.

NCT ID: NCT01643603 Terminated - Multiple Myeloma Clinical Trials

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Start date: May 2012
Phase: Phase 1
Study type: Interventional

This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.